Despite its low incidence, peritoneal mesothelioma manifests with nonspecific symptoms, often leading to delayed diagnosis. Diagnosis relies on imaging techniques, histopathological evaluation, and immunohistochemistry, with emerging molecular markers refining diagnostic accuracy. The cornerstone of treatment is cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, tailored to individual tumor characteristics and patient factors. Future directions involve targeted therapies and immunomodulatory agents, emphasizing multidisciplinary collaboration and translational research. This review aims to enhance understanding and optimize management, ultimately improving outcomes for affected individuals.
No takes yet. Share an insight, caveat, or question.
Nikita et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: